view release on metacpan or  search on metacpan

t/test_set/duration  view on Meta::CPAN

and RA-IV (Percent of Patients) Response Study RA-I Methotrexate Combination ( <START:duration> 24 and 52 weeks <END> ) Study RA-IV Monotherapy ( 24 weeks ) Placebo + MTX
Combination ( 24 and 52 weeks ) Study RA-IV Monotherapy ( <START:duration> 24 weeks <END> ) Placebo + MTX N=199 CIMZIA (a) 200 mg + MTX
1-2 hour infusions of 1 to 5 mg/kg /day AmBisome for <START:duration> 3 to 20 days <END> . The pharmacokinetics of amphotericin B after administration of AmBisome is
(range 0.36 - 34.4 grams ). Median duration of treatment was <START:duration> 24 days <END> (range 5 - 129 days ). Response Rates for Evaluable Patients
34.4 grams ). Median duration of treatment was 24 days (range <START:duration> 5 - 129 days <END> ). Response Rates for Evaluable Patients Patient Group (n) CompleteResponsePartial ResponseTotal
or 0.8 mg/kg /day of amphotericin B deoxycholate for amaximum of <START:duration> 14 days <END> . This study was primarily designed to compare the safety profiles
given COPAXONE 20 mg per mL , subcutaneously every day for <START:duration> 2 years <END> , serum IgG levels reached at least 3 times baseline values
per mL (n=943) or placebo (n=461) three times a week for <START:duration> 12 months <END> . Patients had a median of 2 relapses in the 2
clear, colorless to slightly yellow, sterile, nonpyrogenic solution supplied as: &#x2022; <START:duration> 20 mg per mL <END> in a single-dose, prefilled syringe with a white plunger, in individual
B 5 mg/kg /day for 5-7 days 0.6 mg/kg /day for <START:duration> 42 days <END> a Pharmacokinetic Parameter Mean ± SD Mean ± SD Peak Concentration
Amphotericin B Desoxycholate ABELCET ® Amphotericin B 5 mg/kg /day for <START:duration> 5-7 days <END> 0.6 mg/kg /day for 42 days a Pharmacokinetic Parameter Mean ±
1 after the administration of ABELCET ® 5 mg/kg /day for <START:duration> 7 days <END> . The effect of gender or eth-nicity on the pharmacokinetics of
(N=3), 100 mg (N=3) or 300 mg (N=5) once daily for <START:duration> 14 days <END> with 2 or 3 subjects on placebo. Both plasma aprepitant concentration
dementia in postmenopausal women 65 years of age or older during <START:duration> 5.2 years <END> of treatment with daily CE ( 0.625 mg )-alone, relative to
(MI) in postmenopausal women (50 to 79 years of age) during <START:duration> 5.6 years <END> of treatment with daily oral CE ( 0.625 mg ) combined
dementia in postmenopausal women 65 years of age or older during <START:duration> 4 years <END> of treatment with daily CE ( 0.625 mg ) combined with
brentuximab vedotin to impair male reproductive function and fertility. In a <START:duration> 4-week <END> repeat-dose toxicity study in rats with weekly dosing at 0.5, 5
mg/kg intravenously every 3 weeks . Median duration of treatment was <START:duration> 27 weeks <END> (range, 3 to 56 weeks ) [see Clinical Studies (14.1)]. The
3 weeks . Median duration of treatment was 27 weeks (range, <START:duration> 3 to 56 weeks <END> ) [see Clinical Studies (14.1)]. The most common adverse reactions (&#x2265;20%),
mg/kg intravenously every 3 weeks . Median duration of treatment was <START:duration> 24 weeks <END> (range, 3 to 56 weeks ) [see Clinical Studies (14.2)]. The
3 weeks . Median duration of treatment was 24 weeks (range, <START:duration> 3 to 56 weeks <END> ) [see Clinical Studies (14.2)]. The most common adverse reactions (&#x2265;20%),
patients were exposed to 200 mg /day of oral iron for <START:duration> 21 days <END> . Most patients received their second Feraheme injection 3 to 8